Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.

JOP : Journal of the pancreas - 8 May 2008

Saif Muhammad Wasif, Merikas Irene, Tsimboukis Sotirios, Syrigos Kostas

Abstract excerpt

Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the most common side effects, rash, is possibly linked to overall and progression-free survival and may serve as a potential surrogate marker. Nevertheless,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Exanthema

Share to Genes, erbB-1

Share to Incidence

Share to Pancreatic Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 18469438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.PMID 18469438Read ↗

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.Semantic proximity Read ↗

Severe Rashes Associated With Immunotherapy and Gene Mutations in a Patient With Metastatic Pancreatic CancerSemantic proximity Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity Read ↗

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.Semantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

Eye, Hepatobiliary, and Renal Disorders of Erlotinib in Patients with Non-Small-Cell Lung Cancer: A Meta-AnalysisSemantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.Semantic proximity Read ↗

Osimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.Semantic proximity Read ↗

Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.Semantic proximity Read ↗

HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.